Download presentation

Presentation is loading. Please wait.

Published byTyler Sheer Modified over 6 years ago

1
Switch to EVG/c/FTC/TDF STRATEGY-PI Study STRATEGY-NNRTI Study

2
Design Endpoints –Primary: proportion of patients maintaining HIV RNA 0, assessment for superiority –Secondary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (TLOVR algorithm), CD4, safety, tolerability to W96 Switch to EVG/c/FTC/TDF Continue PI/r + FTC + TDF Arribas J.R. Lancet Infect Dis 2014;14:581-9 STRATEGY-PI Randomisation 2 : 1 Open-label HIV+ ≥ 18 years On FTC + TDF + PI/r HIV RNA 6 months No virologic failure Genotype testing before ART with no resistance to study drugs Integrase inhibitor naïve eGFR > 70 mL/min N = 145 N = 293 W48W96 STRATEGY-PI Study: Switch PI/r to EVG/c

3
EVG/c/FTC/TDF N = 293 PI/r + FTC + TDF N = 140 Median age, years4140 Female15%14% Time since HIV diagnosis, median years44 On first ARV regimen77%83% PI at randomisation Atazanavir42%37% Darunavir39%43% Lopinavir17%16% Fosamprenavir2%4% Saquinavir1%0 CD4 cell count (/mm 3 ), median564585 Hepatitis B / hepatitis C coinfection3% / 7%2% / 7% Discontinuation by W4825 (8.5%)26 (18.6%) Arribas J.R. Lancet Infect Dis 2014;14:581-9 STRATEGY-PI Baseline characteristics and patient disposition

4
Virologic outcome at W48 (mITT, snapshot) EVG/c/FTC/TDF PI/r + FTC + TDF 94 87 % 0 20 40 60 80 100 HIV RNA < 50 c/mL Difference (95% CI) = 6.7% (0.4 ; 13.7) HIV RNA ≥ 50 c/mL 1 1 N = 2 6 12 No virologic data Arribas J.R. Lancet Infect Dis 2014;14:581-9 STRATEGY-PI STRATEGY-PI Study: Switch PI/r to EVG/c

5
EGV/c/FTC/TDFPI/r + FTC + TDF Per-proctol99.5%99.2% Difference: 0.1% (95% CI = - 2.1 ; 3.7) ITT-TLOVR91.7%84.2% Difference: 7.6% (95% CI = 0.9 ; 15.0) Arribas J.R. Lancet Infect Dis 2014;14:581-9 STRATEGY-PI HIV RNA < 50 c/mL Sensitivity and secondary analysis No participants met the criteria for resistance testing (HIV RNA > 400 c/mL at virologic failure or early discontinuation) STRATEGY-PI Study: Switch PI/r to EVG/c

6
Virologic sucess overall and by subgroup at W48 (mITT) Arribas J.R. Lancet Infect Dis 2014;14:581-9 STRATEGY-PI Overall Age < 40 years Age > 40 years Male Female White Non-white Atazanavir Darunavir Lopinavir On first regimen at baseline On second regimen at baseline 0102030405060708090100 Virological success (%) 272/290 121/139 122/130 61/68 150/160 60/71 231/247 103/120 41/43 18/19 217/231 98/113 53/57 22/24 114/121 41/51 107/113 55/60 45/49 20/23 213/225 104/115 53/59 16/23 n/N Favours not switching Switch group No-switch group -50-40-30-20-1001020304050 Difference (%) Favours switching STRATEGY-PI Study: Switch PI/r to EVG/c

7
EVG/c/FTC/TDFPI/r + FTC + TDF Any adverse event,79%74% Grade 3 or 4 AE4%8% Serious adverse event6% Discontinuation because of AEN = 6 (2%)N = 4 (3%) Death0N = 1 Any Grade 3 or 4 laboratory abnormality14%23% Gamma-GT > 5 x ULN3%1% CK ≥ 10 x ULN2%6% ALAT > 5 x ULN2%1% Haematuria2%1% Bilirubin > 2.5 x ULN012% Adverse events and grade3-4 laboratory abnormalities Arribas J.R. Lancet Infect Dis 2014;14:581-9 STRATEGY-PI Improvement in lipids in the switch group HIV Symptom Index : rates of diarrhea and bloating decreased in the switch group Higher tretament satisfaction scores in the switch group

8
Conclusion –Coformulated EVG/c/FTC/TDF is an effective, safe, and tolerable simplification from a PI/r plus FTC and TDF regimen in virologically suppressed, HIV-infected adults with no history of virological failure or resistance to FTC or TDF –Low frequency of virologic failure and absence of emergent resistance in the group switched to EVG/c/FTC/TDF –Rare discontinuations because of adverse events –Nausea more frequent in the switch group ; diarrhea and bloating improved –Small increase in creatinine, moderate improvement in lipids –EVG/c/FTC/TDF is a switch option in virologically suppressed patients with no history of virological failure who want to simplify their existing PI/r regimen, or who have concerns about the long-term safety and side-effects of their existing regimen Arribas J.R. Lancet Infect Dis 2014;14:581-9 STRATEGY-PI STRATEGY-PI Study: Switch PI/r to EVG/c

Similar presentations

© 2021 SlidePlayer.com Inc.

All rights reserved.

To make this website work, we log user data and share it with processors. To use this website, you must agree to our Privacy Policy, including cookie policy.

Ads by Google